, Tracking Stock Market Picks
Enter Symbol:
Cellectar Biosciences Inc. (CLRB) [hlAlert]

Mkt Outperform
down 65.55 %

Novelos Therapeutics, Inc. (NVLT) rated Mkt Outperform with price target $2.50 by Burrill Institutional Research

Posted on: Friday,  May 17, 2013  8:25 AM ET by Burrill Institutional Research

Burrill Institutional Research rated Mkt Outperform Cellectar Biosciences Inc. (NASDAQ: CLRB) on 05/17/2013, when the stock price was $9.00.
Since then, Cellectar Biosciences Inc. has lost 65.56% as of 08/25/2015's recent price of $3.10.
If you would have followed this Burrill Institutional Research's recommendation on CLRB, you would have lost 65.55% of your investment in 830 days.

Novelos Therapeutics, Inc. (Novelos) is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the Company?s lead compound, is in Phase III development for treatment of lung cancer under a special protocol assessment and fast track. NOV-002 is also in Phase II development for treatment of early-stage breast cancer and chemotherapy-resistant ovarian cancer. NOV-205, Novelos? second compound, is in Phase Ib development for chronic hepatitis C non responders. Both compounds have completed clinical trials in humans and have been approved for use in Russia where they were originally developed.

Burrill Institutional Research
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/17/2013 8:25 AM Buy
9.00 50.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy